Predicting morphological and functional variations of benign adrenal incidentalomas in relation to initial characteristics.

Cushing’s syndrome adrenal incidentaloma attenuation value autonomous cortisol secretion non-functional adrenal incidentaloma

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 04 03 2023
accepted: 23 05 2023
medline: 26 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

The follow-up strategy for unresected non-functional adrenal tumors (NFAT) is a major controversial issue in endocrinological clinical practice, as the natural history of adrenal incidentalomas (AI) is partially unknown and a consensus on their adequate management is lacking. In a recent longitudinal study by Ceccato et al., a large cohort of patients with conservatively treated AI were evaluated for possible radiological variations over time and their relationship with autonomous cortisol secretion (ACS). Starting from this paper, we performed a literature review of available longitudinal studies focus on the same issue. Notwithstanding the high variability in the duration of follow-up and in the criteria used to define ACS in the included studies, our findings support the idea that there is a not negligible risk of morphological and functional changes, which may have metabolic implications, especially after 5-10 years of follow-up. Unfortunately, these variations seem to be scarcely predictable. Therefore, it may be risky to interrupt the follow-up in patients with NFAT, in particular in the presence of larger diameter of the adenoma and higher cortisol levels at diagnosis. These results should be considered in defining the optimal management of these patients.

Identifiants

pubmed: 37347112
doi: 10.3389/fendo.2023.1179817
pmc: PMC10280065
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1179817

Informations de copyright

Copyright © 2023 Parazzoli, Favero, Aresta and Morelli.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Diabetes Endocrinol. 2020 Nov;8(11):894-902
pubmed: 33065059
Clin Endocrinol (Oxf). 2009 May;70(5):674-9
pubmed: 19067718
Br J Cancer. 2005 Mar 28;92(6):1104-9
pubmed: 15770213
Endocrine. 2010 Feb;37(1):40-6
pubmed: 19882253
Ann Intern Med. 2022 Oct;175(10):1383-1391
pubmed: 36095315
Ann Endocrinol (Paris). 2008 Dec;69(6):487-500
pubmed: 19022420
Korean J Intern Med. 2013 Sep;28(5):557-64
pubmed: 24009451
Front Endocrinol (Lausanne). 2021 Dec 02;12:794197
pubmed: 34925247
Eur J Endocrinol. 2009 Feb;160(2):257-64
pubmed: 18974229
Endocr Connect. 2021 Jun 16;10(6):637-645
pubmed: 34010150
Eur J Endocrinol. 2017 Dec;177(6):475-483
pubmed: 28870984
Eur J Endocrinol. 2002 Oct;147(4):489-94
pubmed: 12370111
Endocrine. 2021 Jan;71(1):178-188
pubmed: 32915435
Ann Intern Med. 2022 Mar;175(3):325-334
pubmed: 34978855
J Endocrinol Invest. 2021 Nov;44(11):2349-2357
pubmed: 33683661
Ann Intern Med. 2019 Jul 16;171(2):107-116
pubmed: 31234202
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1181-e1192
pubmed: 34665854
Endocr Pract. 2020 Dec;26(12):1406-1415
pubmed: 33471732
J Clin Endocrinol Metab. 2000 Feb;85(2):637-44
pubmed: 10690869
Eur J Endocrinol. 2016 Aug;175(2):G1-G34
pubmed: 27390021
Exp Clin Endocrinol Diabetes. 2021 May;129(5):349-356
pubmed: 31958848
J Endocrinol Invest. 2010 Jan;33(1):32-6
pubmed: 19542759
Clin Endocrinol (Oxf). 2017 Apr;86(4):488-498
pubmed: 27992961
Endocr Pract. 2009 Jul-Aug;15(5):450-3
pubmed: 19632968
AJR Am J Roentgenol. 2008 May;190(5):1163-8
pubmed: 18430826
Endokrynol Pol. 2016;67(2):234-58
pubmed: 27082051
Ann Intern Med. 2003 Mar 4;138(5):424-9
pubmed: 12614096
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31900474
J Clin Endocrinol Metab. 1999 Feb;84(2):520-6
pubmed: 10022410

Auteurs

Chiara Parazzoli (C)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Vittoria Favero (V)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Carmen Aresta (C)

Endocrinology Department & Lab of Endocrine and Metabolic Research, IRCCS-Istituto Auxologico Italiano, Milan, Italy.

Valentina Morelli (V)

Endocrinology Department & Lab of Endocrine and Metabolic Research, IRCCS-Istituto Auxologico Italiano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH